keyword
MENU ▼
Read by QxMD icon Read
search

Entecavir

keyword
https://www.readbyqxmd.com/read/28627473/glycyrrhetic-acid-but-not-glycyrrhizic-acid-strengthened-entecavir-activity-by-promoting-its-subcellular-distribution-in-the-liver-via-efflux-inhibition
#1
Qianying Chen, Hongzhu Chen, Wenjie Wang, Jiali Liu, Wenyue Liu, Ping Ni, Guowei Sang, Guangji Wang, Fang Zhou, Jingwei Zhang
Entecavir (ETV) is a superior nucleoside analogue used to treat hepatitis B virus (HBV) infection. Although its advantages over other agents include low viral resistance and the elicitation of a sharp decrease in HBV DNA, adverse effects such as hepatic steatosis, hepatic damage and lactic acidosis have also been reported. Glycyrrhizin has long been used as hepato-protective medicine. The clinical combination of ETV plus glycyrrhizin in China displays better therapeutic effects and lower rates of liver damage...
June 13, 2017: European Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/28623307/both-interferon-alpha-and-lambda-can-reduce-all-intrahepatic-hdv-infection-markers-in-hbv-hdv-infected-humanized-mice
#2
Katja Giersch, Maria Homs, Tassilo Volz, Martina Helbig, Lena Allweiss, Ansgar W Lohse, Jörg Petersen, Maria Buti, Teresa Pollicino, Camille Sureau, Maura Dandri, Marc Lütgehetmann
Co-infection with hepatitis B (HBV) and D virus (HDV) is associated with the most severe course of liver disease. Interferon represents the only treatment currently approved. However, knowledge about the impact of interferons on HDV in human hepatocytes is scant. Aim was to assess the effect of pegylated interferon alpha (peg-IFNα) and lambda (peg-IFNλ), compared to the HBV-polymerase inhibitor entecavir (ETV) on all HDV infection markers using human liver chimeric mice and novel HDV strand-specific qRT-PCR and RNA in situ hybridization assays, which enable intrahepatic detection of HDV RNA species...
June 16, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28622419/the-risk-of-hepatocellular-carcinoma-is-decreasing-after-the-first-5-years-of-entecavir-or-tenofovir-in-caucasians-with-chronic-hepatitis-b
#3
George V Papatheodoridis, Ramazan Idilman, George N Dalekos, Maria Buti, Heng Chi, Florian van Boemmel, Jose Luis Calleja, Vana Sypsa, John Goulis, Spilios Manolakopoulos, Alessandro Loglio, Spyros Siakavelas, Onur Keskın, Nikolaos Gatselis, Bettina E Hansen, Maria Lehretz, Juan de la Revilla, Savvoula Savvidou, Anastasia Kourikou, Ioannis Vlachogiannakos, Kostantinos Galanis, Cihan Yurdaydin, Thomas Berg, Massimo Colombo, Rafael Esteban, Harry L A Janssen, Pietro Lampertico
Whether there is a change of hepatocellular carcinoma (HCC) incidence in chronic hepatitis B (CHB) patients under long-term therapy with potent nucleos(t)ide analogues is currently unclear. We therefore assessed the HCC incidence beyond year 5 of entecavir/tenofovir therapy and tried to determine possible factors associated with late HCC occurrence. This European 10-center, cohort study included 1951 adult Caucasian CHB patients without HCC at baseline who received entecavir/tenofovir for ≥1 year. Of them, 1205 (62%) patients without HCC within the first 5 years of therapy have been followed for 5-10 (median: 6...
June 16, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28614914/ip-10-expression-in-patients-with-chronic-hbv-infection-and-its-ability-to-predict-the-decrease-in-hbsag-levels-after-treatment-with-entecavir
#4
Kai Zhao, Tao Yang, Mimi Sun, Wei Zhang, Yong An, Gang Chen, Lei Jin, Qinghua Shang, Wengang Song
Interferon-γ-inducible protein 10 (IP-10), also known as chemokine C-X-C motif ligand (CXCL) 10, is closely associated with antiviral immunity and the progression of chronic hepatitis B (CHB). However, the value of baseline serological and histological IP-10 expression levels in predicting the efficacy of the antiviral response to nucleoside/nucleotide analogues (NAs) is still unknown. In our research, intrahepatic and peripheral IP-10 expression levels were systemically examined before and after treatment with entecavir (ETV)...
June 14, 2017: Molecules and Cells
https://www.readbyqxmd.com/read/28611778/peg-interferon-lambda-treatment-induces-robust-innate-and-adaptive-immunity-in-chronic-hepatitis-b-patients
#5
Sandra Phillips, Sameer Mistry, Antonio Riva, Helen Cooksley, Tanya Hadzhiolova-Lebeau, Slava Plavova, Krum Katzarov, Marieta Simonova, Stephan Zeuzem, Clive Woffendin, Pei-Jer Chen, Cheng-Yuan Peng, Ting-Tsung Chang, Stefan Lueth, Robert De Knegt, Moon-Seok Choi, Heiner Wedemeyer, Michael Dao, Chang-Wook Kim, Heng-Chen Chu, Megan Wind-Rotolo, Roger Williams, Elizabeth Cooney, Shilpa Chokshi
IFN-lambda (IFNλ) is a member of the type III IFN family and is reported to possess anti-pathogen, anti-cancer, and immunomodulatory properties; however, there are limited data regarding its impact on host immune responses in vivo. We performed longitudinal and comprehensive immunosurveillance to assess the ability of pegylated (peg)-IFNλ to augment antiviral host immunity as part of a clinical trial assessing the efficacy of peg-IFNλ in chronic hepatitis B (CHB) patients. These patients were pretreated with directly acting antiviral therapy (entecavir) for 12 weeks with subsequent addition of peg-IFNλ for up to 32 weeks...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/28588691/chronic-hepatitis-b-patients-with-high-liver-fibrosis-levels-should-receive-antiviral-treatment
#6
Xu Li, Qinglong Jin, Hongqin Xu, Zetian Zhang, Hongjie Zhou, Dongqing Yan, Dongmei Li, Pujun Gao, Junqi Niu
The present study aimed to evaluate improvements in liver stiffness (LS) measured by transient elastography (TE) and associated factors in Chinese patients with chronic hepatitis B (CHB) treated with entecavir (ETV). A total of 190 consecutive CHB patients who received entecavir therapy and two LS measurements (LSMs) were enrolled in this retrospective study (average age, 47 years; 137 males [72.1%]), including 111 patients without liver cirrhosis (group 0) and 79 patients with liver cirrhosis (group 1). Each patient received LSM twice with an interval of six months...
June 2017: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/28586757/nucleoside-analogs-treatment-delay-the-onset-of-hepatocellular-carcinoma-in-patients-with-hbv-related-cirrhosis
#7
Jingfeng Bi, Zheng Zhang, Enqiang Qin, Jun Hou, Shuiwen Liu, Zengmin Liu, Shuo Li, Zhenman Wei, Yanwei Zhong
Whether Nucleoside analogs (NA) treatment can delay the onset of HCC remains unclear. We retrospectively analyzed the clinical data of patients with HBV-related cirrhosis and HCC from 2000 to 2012. Cox proportional hazards model was used to explore the association between NA treatment and postponement of HCC development, the dependent variable was time interval from cirrhosis treatment towards the onset of HCC, and the covariates included age, sex, family history, compensation status at baseline. A total of 1155 HCC patients treated with NAs (n = 528, lamivudine, adefovir, entecavir) and non NA (n = 627) for more than 24 months before the occurrence of HCC were incorporated into the cohort...
May 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/28574799/a-novel-entecavir-analogue-constructing-with-a-spiro-2-4-heptane-core-structure-in-the-aglycon-moiety-its-synthesis-and-evaluation-for-anti-hepatitis-b-virus-activity
#8
Hiroki Kumamoto, Misato Fukano, Shuhei Imoto, Satoru Kohgo, Yuki Odanaka, Masayuki Amano, Nobuyo Kuwata-Higashi, Hiroaki Mitsuya, Kazuhiro Haraguchi, Kiyoshi Fukuhara
Synthesis of a novel 2'-deoxy-guanine carbocyclic nucleoside 4 constructed with spiro[2.4]heptane core structure in the aglycon moiety was carried out. Radical-mediated 5-exo-dig mode cyclization and following cyclopropanation proceeded efficiently to furnish the spiro alcohol 10. Subsequent Mitsunobu-type glycosylation between 13 and 14, deoxygenation of the 2'-hydroxyl group of 16 and deprotection of 17 gave the title compound 4. Compound 4 demonstrated moderate anti-HBV activity (EC50 value of 0.12 ± 0...
June 2, 2017: Nucleosides, Nucleotides & Nucleic Acids
https://www.readbyqxmd.com/read/28562554/effectiveness-of-entecavir-or-telbivudine-therapy-in-patients-with-chronic-hepatitis-b-virus-infection-pre-treated-with-interferon-compared-with-de-novo-therapy-with-entecavir-and-telbivudine
#9
Shaohang Cai, Jiawei Cao, Tao Yu, Muye Xia, Jie Peng
Little is known about the optimal treatment following the initial failure of interferon therapy and the potential different efficacy with de novo therapy with entecavir (ETV) or telbivudine (LDT) and following the interferon therapy failure.ETV or LDT therapy following the interferon therapy failure was compared with that of de novo therapy with ETV or LDT in patients with chronic hepatitis B virus (HBV) infection. Treatment parameters included virological response, hepatitis B e antigen (HBeAg) seroconversion, and alanine aminotransferase (ALT) normalization...
June 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28562104/liver-cirrhosis-stages-and-the-incidence-of-hepatocellular-carcinoma-in-chronic-hepatitis-b-patients-receiving-antiviral-therapy
#10
Jae-Jun Shim, Chi Hyuck Oh, Jung Wook Kim, Chang Kyun Lee, Byung-Ho Kim
OBJECTIVES: Long-term antiviral therapy decreases the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB), however, it cannot eliminate the risk. We investigated the incidence of HCC at different stages of liver cirrhosis (LC) and identified clinical predictors for HCC development during antiviral therapy. METHODS: The data from 356 treatment-naïve patients aged 40 to 69 years without a history of HCC who had received entecavir for ≥6 months were collected retrospectively...
May 31, 2017: Scandinavian Journal of Gastroenterology
https://www.readbyqxmd.com/read/28554002/retrospective-analysis-of-hepatitis-b-virus-chronic-infection-in-247-patients-clinical-stages-response-to-treatment-and-poor-prognostic-factors
#11
Marlone Cunha-Silva, Fábio R T Marinho, Paulo F Oliveira, Tirzah M Lopes, Tiago Sevá-Pereira, Sonia L S Lorena, Jazon R S Almeida
BACKGROUND: Chronic hepatitis B is a major cause of cirrhosis, and the natural history of the disease has several clinical stages that should be thoroughly understood for the implementation of proper treatment. Nonetheless, curing the disease with antiviral treatment remains a challenge. AIMS: To describe the clinical course, response to treatment, and poor prognostic factors in 247 hepatitis B virus chronic infection patients treated in a tertiary hospital in Brazil...
May 26, 2017: Brazilian Journal of Infectious Diseases
https://www.readbyqxmd.com/read/28540167/t-cell-associated-immunoregulation-and-antiviral-effect-of-oxymatrine-in-hydrodynamic-injection-hbv-mouse-model
#12
Xiuxiu Sang, Ruilin Wang, Yanzhong Han, Cong'en Zhang, Honghui Shen, Zhirui Yang, Yin Xiong, Huimin Liu, Shijing Liu, Ruisheng Li, Ruichuang Yang, Jiabo Wang, Xuejun Wang, Zhaofang Bai, Xiaohe Xiao
Although oxymatrine (OMT) has been shown to directly inhibit the replication of hepatitis B virus (HBV) in vitro, limited research has been done with this drug in vivo. In the present study, the antiviral effect of OMT was investigated in an immunocompetent mouse model of chronic HBV infection. The infection was achieved by tail vein injection of a large volume of DNA solution. OMT (2.2, 6.7 and 20 mg/kg) was administered by daily intraperitoneal injection for 6 weeks. The efficacy of OMT was evaluated by the levels of HBV DNA, hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg) and hepatitis B core antigen (HBcAg)...
May 2017: Acta Pharmaceutica Sinica. B
https://www.readbyqxmd.com/read/28538268/etiological-factors-of-chronic-hepatitis-in-italy-a-2014-national-survey
#13
Tommaso Stroffolini, Evangelista Sagnelli, Piero L Almasio, Angelo Andriulli, Antonina Smedile, Mario Pirisi, Caterina Sagnelli, Maurizio Russello, Nicola Coppola, Massimo de Luca, Mariantonietta Pisaturo, Floriano Rosina, Giovanni B Gaeta
BACKGROUND: The last Italian prevalence survey on chronic hepatitis (CH) conducted in 2001 showed that the hepatitis C virus (HCV) was the main agent associated with CH. AIM: The aim of this study was to evaluate epidemiological changes in CH occurring after 13 years. PATIENTS AND METHODS: Enrollment of 1392 CH consecutive patients referred to 16 Italian liver units in 2014 scattered all over the country (four in the North, four in the Center, four in the South, and four in the Islands) was performed...
May 19, 2017: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28538267/cirrhosis-has-no-impact-on-therapeutic-responses-of-entecavir-for-chronic-hepatitis-b
#14
Pin-Chao Wang, Tao-Yang Wei, Tai-Chung Tseng, Hans Hsienhong Lin, Chia-Chi Wang
OBJECTIVE: As the efficacy of a direct antiviral agent is reduced in cirrhotic chronic hepatitis C patients, prolonged duration of treatment or addition of ribavirin is recommended to improve the rates of sustained virological response. However, the impact of cirrhosis on the efficacy of antiviral treatment for chronic hepatitis B (CHB) remained unclear. PATIENTS AND METHODS: This retrospective cohort study screened entecavir (ETV)-treated CHB patients in Taipei Tzu Chi Hospital from January 2007 till October 2014...
May 19, 2017: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28522916/early-hepatitis-b-viral-dna-clearance-predicts-treatment-response-at-week-96
#15
Xiao-Yu Fu, De-Ming Tan, Cui-Mei Liu, Bin Gu, Li-Hua Hu, Zhong-Tian Peng, Bin Chen, Yuan-Lin Xie, Huan-Yu Gong, Xiao-Xuan Hu, Lian-Hui Yao, Xiao-Ping Xu, Zheng-Yuan Fu, Lang-Qiu He, Si-Hai Li, Yun-Zhu Long, De-Hui Li, Ji-Long Gu, Shi-Fang Peng
AIM: To investigate whether hepatitis viral DNA load at 24 wk of treatment predicts response at 96 wk in patients with chronic hepatitis B. METHODS: A total of 172 hepatitis B envelope antigen (HBeAg)-positive chronic hepatitis B patients who received initial treatment at 16 tertiary hospitals in Hunan Province, China were enrolled in this study. All patients received conventional doses of lamivudine and adefovir dipivoxil, telbivudine, entecavir dispersible tablets, or entecavir tablets for 96 wk...
April 28, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28521532/new-antivirals-for-the-treatment-of-chronic-hepatitis-b
#16
Vincent Soriano, Pablo Barreiro, Laura Benitez, Jose M Peña, Carmen de Mendoza
Current treatment with oral nucleos(t)ides entecavir or tenofovir provide sustained suppression of HBV replication and clinical benefit in most chronic hepatitis B virus (HBV) infected persons. However, HBV rebound generally occurs upon drug discontinuation due to persistence of genomic HBV reservoirs as episomic cccDNA and chromosomic integrated HBV-DNA. There is renewed enthusiasm on HBV drug discovery following recent successes with antivirals for hepatitis C and immunotherapies for some cancers. Areas covered: New drugs that target distinct steps of the HBV life cycle are been developed, including inhibitors of viral entry, new polymerase inhibitors, capsid and assembly inhibitors, virus release blockers, and disruptors of cccDNA formation and transcription...
May 26, 2017: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/28511283/a-different-inhibitor-is-required-for-overcoming-entecavir-resistance-a-comparison-of-four-rescue-therapies-in-a-retrospective-study
#17
Guosheng Yuan, Chengguang Hu, Yuchen Zhou, Junwei Liu, Huaping Huang, Yuan Li, Dinghua Yang, Fuyuan Zhou, Yong-Yuan Zhang, Yuanping Zhou
AIMS: Little clinical data are available regarding reestablishing the effective inhibition of entecavir (ETV)-resistant mutants. In this retrospective study, we aimed to compare the efficacies of four treatment regimens as rescue therapy for those chronic hepatitis B (CHB) patients with ETV resistance. METHODS: A total of 65 patients with ETV resistance were assigned either with tenofovir disoproxil fumarate (TDF) monotherapy (n=21), ETV (0.5 mg) plus adefovir (ADV) combination therapy (n=19), ETV (1...
May 16, 2017: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28506056/risk-score-model-for-the-development-of-hepatocellular-carcinoma-in-treatment-na%C3%A3-ve-patients-receiving-oral-antiviral-treatment-for-chronic-hepatitis-b
#18
Won Sohn, Ju-Yeon Cho, Ji Hoon Kim, Jung Il Lee, Hyung Joon Kim, Min-Ah Woo, Sin-Ho Jung, Yong-Han Paik
Background/Aims: This study aimed to develop and validate a risk prediction model for the development of hepatocellular carcinoma (HCC) in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B (CHB). Methods: We investigated 2,061 Korean treatment-naïve patients with CHB treated with entecavir as an initial therapy. A risk score model for HCC development was developed based on multivariable Cox regression model in a single center (n=990) and was validated using the time-dependent area under the receiver operating characteristic curve (AUROC) in three other centers (n=1,071)...
May 16, 2017: Clinical and Molecular Hepatology
https://www.readbyqxmd.com/read/28502443/hepatitis-b-and-c
#19
REVIEW
Wikrom Karnsakul, Kathleen B Schwarz
Chronic viral hepatitis is a global health threat and financial burden. Hepatitis B and C viruses (HBV and HCV) are the most common causes of chronic viral hepatitis in the United States. Most cases are asymptomatic before adulthood. Research has resulted in effective therapy for HCV and the promise of effective therapies for HBV. For HCV, therapy is pegylated interferon and ribavirin. Clinical trials with effective direct-acting antiviral agents are underway in pediatrics. For HBV, approved agents are alpha-interferon, lamivudine, adefovir, tenofovir, and entecavir...
June 2017: Pediatric Clinics of North America
https://www.readbyqxmd.com/read/28500322/incidence-and-predictors-of-hbv-relapse-after-cessation-of-nucleoside-analogues-in-hbeag-negative-patients-with-hbsag%C3%A2-%C3%A2-%C3%A2-200%C3%A2-iu-ml
#20
Chih-Chien Yao, Chao-Hung Hung, Tsung-Hui Hu, Sheng-Nan Lu, Jing-Hung Wang, Chung-Mo Lee, Chien-Hung Chen
The predictors of hepatitis B virus (HBV) relapse and HBsAg loss after cessation of nucleos(t)ide analogues (NA) in HBeAg-negative patients with end-of-treatment HBsAg ≤ 200 IU/mL remains unclear. The study recruited 119 chronic hepatitis B (CHB) patients who achieved end-of-treatment HBsAg ≤ 200 IU/mL, were treated with lamivudine (n = 34) and entecavir (n = 85). The 5-year rates of post-treatment virological relapse, clinical relapse, and HBsAg loss at 60 months were 39.4%, 27.6%, and 45...
May 12, 2017: Scientific Reports
keyword
keyword
2107
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"